Skip to main content
Year archive

Lupin Ltd — 2025 filings

All 407 regulatory filings released by Lupin Ltd (LUPIN) in 2025, sourced directly from the official regulator.

407 Filings
2025 Period
2025 filings (407)
Filing Released Lang
Update of acquisition of VISUfarma B.V., the Netherlands.
Capital/Financing Update
2025-12-30 English
General Updates
M&A Activity
2025-12-30 English
Lupin signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist.
Regulatory Filings
2025-12-29 English
Press Release
Capital/Financing Update
2025-12-29 English
Trading Window
Regulatory Filings
2025-12-26 English
Intimation of Closure of Trading Window
Regulatory Filings
2025-12-26 English
Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil in the Philippines and Brazil.
Capital/Financing Update
2025-12-18 English
Press Release
Capital/Financing Update
2025-12-18 English
Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab.
Regulatory Filings
2025-12-17 English
Press Release
Regulatory Filings
2025-12-17 English
Press Release
Regulatory Filings
2025-12-16 English
Receipt of Establishment Inspection Report (EIR) by the Company from the U.S. FDA for its injectables facility in Nagpur, India.
Regulatory Filings
2025-12-16 English
Press Release
Environmental & Social Information
2025-12-16 English
Lupin Secures SBTi Validation for Emission Reduction Targets.
Environmental & Social Information
2025-12-16 English
Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain.
Regulatory Filings
2025-12-12 English
Press Release
Regulatory Filings
2025-12-12 English
Newspaper Publication for the information regarding Special Window for re-lodgement for transfer request of physical shares.
Regulatory Filings
2025-12-11 English
Copy of Newspaper Publication
Regulatory Filings
2025-12-11 English
Intimation regarding allotment of 36626 shares under ESOP.
Share Issue/Capital Change
2025-12-10 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-12-10 English
ESG Rating by NSE Sustainability Ratings & Analytics Limited.
Environmental & Social Information
2025-12-09 English
General Updates
Environmental & Social Information
2025-12-09 English
Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets.
Regulatory Filings
2025-12-05 English
Press Release
Regulatory Filings
2025-12-05 English
Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.
Regulatory Filings
2025-12-04 English
Press Release
Regulatory Filings
2025-12-04 English
Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne).
Regulatory Filings
2025-12-01 English
Press Release
Regulatory Filings
2025-12-01 English
Lupin Foundation Earns CRISIL''s Highest VO 1A Rating for Excellence in Social Responsibility.
Regulatory Filings
2025-11-28 English
Press Release
Regulatory Filings
2025-11-28 English
General Updates
Regulatory Filings
2025-11-21 English
U.S. FDA has conducted an inspection at Company''s manufacturing facility located at Goa, India.
Regulatory Filings
2025-11-21 English
Press Release
Regulatory Filings
2025-11-15 English
Lupin announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations.
Regulatory Filings
2025-11-15 English
Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT Exclusivity in the U.S., the first product from its proprietary Long-Acting Injectable platform PrecisionSphere.
Regulatory Filings
2025-11-14 English
Press Release
Regulatory Filings
2025-11-14 English
Press Release
Environmental & Social Information
2025-11-13 English
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91.
Environmental & Social Information
2025-11-13 English
Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
Regulatory Filings
2025-11-12 English
Press Release
Regulatory Filings
2025-11-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2025-11-12 English
Transcript of Q2 FY2026 Earnings Conference Call.
Call Transcript
2025-11-12 English
Press Release
Regulatory Filings
2025-11-12 English
Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India.
Regulatory Filings
2025-11-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-11-10 English
Intimation about participating in the Analyst/Investors Meet.
Regulatory Filings
2025-11-10 English
Press Release
Regulatory Filings
2025-11-08 English
Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment.
Regulatory Filings
2025-11-08 English
Copy of Newspaper Publication
Regulatory Filings
2025-11-08 English
Copy of Newspaper Publication in respect of Unaudited Financial Results of the Company for quarter and half year ended September 30, 2025.
Regulatory Filings
2025-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-11-07 English
Link of Audio Recording of the Earnings Call-Q2 FY26.
Regulatory Filings
2025-11-07 English
Investor Presentation
Investor Presentation
2025-11-06 English
The Company has informed the Exchange about the Investor Presentation on the Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.
Investor Presentation
2025-11-06 English
Press Release
Earnings Release Q2 2026
2025-11-06 English
Lupin Q2 FY2026 Results
Earnings Release Q2 2026
2025-11-06 English
Outcome of the Board Meeting for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended September 30, 2025.
Regulatory Filings
2025-11-06 English
Outcome of Board Meeting
Interim / Quarterly Report H1 2026
2025-11-06 English
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.
Regulatory Filings
2025-11-06 English
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility
Regulatory Filings
2025-11-05 English
Press Release
Regulatory Filings
2025-11-05 English
Copy of Newspaper Publication
Regulatory Filings
2025-10-31 English
Newspaper Advertisement for the intimation regarding Special Window for re-lodgement for transfer request of physical shares.
Regulatory Filings
2025-10-31 English
Press Release
Regulatory Filings
2025-10-30 English
Lupin Digital Health Launches VITALYFE. .
Regulatory Filings
2025-10-30 English
Inauguration of Lupin''s New Corporate Offices in Bridgewater, New Jersey.
Regulatory Filings
2025-10-28 English
Press Release
Regulatory Filings
2025-10-28 English
Intimation regarding allotment of 4312 shares under ESOPs.
Share Issue/Capital Change
2025-10-28 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-10-28 English
Schedule of Earnings Call for Unaudited Financial Results of Q2 FY26.
Regulatory Filings
2025-10-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-10-27 English
Lupin Launches Authorized Generic Version of Ravicti in the United States.
Regulatory Filings
2025-10-24 English
Press Release
Regulatory Filings
2025-10-24 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-22 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings
2025-10-22 English
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Regulatory Filings
2025-10-22 English
Press Release
Regulatory Filings
2025-10-13 English
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025.
Regulatory Filings
2025-10-13 English
U.S. FDA has conducted a Pre-Approval Inspection at the Company''s manufacturing facility located in Somerset, New Jersey, U.S.A.
Regulatory Filings
2025-10-11 English
General Updates
Regulatory Filings
2025-10-11 English
ESOP/ESOS/ESPS
Capital/Financing Update
2025-10-10 English
Intimation regarding grant of 14649 stock options under ESOP.
Share Issue/Capital Change
2025-10-10 English
Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform.
Regulatory Filings
2025-10-09 English
Press Release
Regulatory Filings
2025-10-09 English
Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida, U.S.A.
Capital/Financing Update
2025-10-08 English
Press Release
Capital/Financing Update
2025-10-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-10-07 English
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2025.
Regulatory Filings
2025-10-07 English
U.S. FDA has determined the inspection of Company''s Pithampur Unit-2 manufacturing facility as Official Action Indicated.
Regulatory Filings
2025-10-04 English
Updates
Regulatory Filings
2025-10-04 English
Press Release
Regulatory Filings
2025-10-03 English
Lupin Launches Liraglutide Injection in the United States.
Regulatory Filings
2025-10-03 English
Press Release
Regulatory Filings
2025-10-01 English
Lupin Launches Rivaroxaban for Oral Suspension in the United States.
Regulatory Filings
2025-10-01 English
Press Release
Regulatory Filings
2025-09-30 English
Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension.
Regulatory Filings
2025-09-30 English
Retirement of Senior Management Personnel
Board/Management Information
2025-09-30 English
Retirement
Board/Management Information
2025-09-30 English
Nanomi B.V., the Netherlands, a wholly owned subsidiary of the Company in Netherlands, has entered into a definitive agreement to acquire the entire share capital of VISUfarma B.V., headquartered ....
M&A Activity
2025-09-29 English
Acquisition
M&A Activity
2025-09-29 English
Trading Window
Regulatory Filings
2025-09-26 English
Intimation of Closure of Trading Window.
Regulatory Filings
2025-09-26 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements
2025-09-25 English
Details of voting results of the business transacted by way of Postal Ballot along with report of the Scrutinizer.
Declaration of Voting Results & Voting Rights Announcements
2025-09-25 English
Details of voting results of the business transacted by way of Postal Ballot along with report of the Scrutinizer.
Declaration of Voting Results & Voting Rights Announcements
2025-09-25 English
Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets.
Regulatory Filings
2025-09-24 English
Press Release
Regulatory Filings
2025-09-24 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-09-23 English
Intimation regarding allotment of 3351 shares under ESOP.
Share Issue/Capital Change
2025-09-23 English
U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company''s Pune Biotech facility.
Regulatory Filings
2025-09-20 English
General Updates
Regulatory Filings
2025-09-20 English
Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules.
Regulatory Filings
2025-09-17 English
Press Release
Regulatory Filings
2025-09-17 English
U.S. FDA has conducted an inspection of Company''s Injectable facility at Nagpur.
Regulatory Filings
2025-09-16 English
General Updates
Regulatory Filings
2025-09-16 English
ESG Rating by ESG Risk Assessments and Insights Limited.
Regulatory Filings
2025-09-13 English
General Updates
Regulatory Filings
2025-09-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-09-11 English
Intimation about participating in the Analyst/Investors Meet.
Regulatory Filings
2025-09-11 English
Updates
Regulatory Filings
2025-09-06 English
U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company''s Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility.
Regulatory Filings
2025-09-06 English
Newspaper Publication for the information regarding Special Window for re-lodgement for transfer request of physical shares.
AGM Information
2025-09-03 English
Copy of Newspaper Publication
AGM Information
2025-09-03 English
Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi''s Long-Acting Injectable Platform.
Regulatory Filings
2025-09-03 English
Press Release
Regulatory Filings
2025-09-03 English
General Updates
Environmental & Social Information
2025-08-29 English
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
Environmental & Social Information
2025-08-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-08-27 English
Intimation about participating in the Analyst/Investors Meet.
Regulatory Filings
2025-08-27 English
Copy of Newspaper Publication
Report Publication Announcement
2025-08-27 English
Copies of Newspaper Publication with respect to dispatch of Postal Ballot Notice.
AGM Information
2025-08-27 English
Notice of Postal Ballot dated August 20, 2025, along with explanatory Statement.
Proxy Solicitation & Information Statement
2025-08-26 English
Shareholders meeting
Proxy Solicitation & Information Statement
2025-08-26 English
Intimation regarding allotment of 7189 shares under ESOP.
Share Issue/Capital Change
2025-08-21 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-08-21 English
Change in Director(s)
Board/Management Information
2025-08-20 English
Re-appointment of Mr. Mark D. McDade, Independent Director for Second term of five consecutive years.
Board/Management Information
2025-08-20 English
Lupin Launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity.
Regulatory Filings
2025-08-20 English
Press Release
Regulatory Filings
2025-08-20 English
Lupin Announces Licensing Deal for Ranibizumab Biosimilar.
Regulatory Filings
2025-08-12 English
Press Release
Capital/Financing Update
2025-08-12 English
Completion of term of Mr. Jean-Luc Belingard as an Independent Director of the Company.
Board/Management Information
2025-08-11 English
Change in Director(s)
Board/Management Information
2025-08-11 English
Details of Voting Results of Forty-Third Annual General Meeting of the Company and Consolidated Scrutinizer''s Report.
Regulatory Filings
2025-08-11 English
Shareholders meeting
Regulatory Filings
2025-08-11 English
Proceedings of the Forty-Third Annual General Meeting held on August 11, 2025.
Regulatory Filings
2025-08-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2025-08-11 English
Transcript of Q1 FY2026 Earnings Conference Call.
Call Transcript
2025-08-11 English
Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States.
Regulatory Filings
2025-08-11 English
Press Release
Regulatory Filings
2025-08-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-08-08 English
Intimation about participating in the Analyst / Institutional Investors Meet.
Regulatory Filings
2025-08-08 English
Copy of Newspaper Publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2025.
Report Publication Announcement
2025-08-07 English
Copy of Newspaper Publication
Regulatory Filings
2025-08-07 English
Audio recording of the Earnings Call-Q1 FY26
Regulatory Filings
2025-08-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-08-06 English
The Company has informed the Exchange about Investor Presentation on the Unaudited Financial Results for the quarter ended on June 30, 2025.
Investor Presentation
2025-08-06 English
Investor Presentation
Investor Presentation
2025-08-06 English
Lupin Q1 FY2026 Results
Interim / Quarterly Report Q1 2026
2025-08-05 English
Press Release
Interim / Quarterly Report Q1 2026
2025-08-05 English
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025.
Regulatory Filings
2025-08-05 English
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025.
Regulatory Filings
2025-08-05 English
Outcome of Board Meeting
Regulatory Filings
2025-08-05 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-08-05 English
Disclosure regarding Grant of 14420 stock options under ESOP.
Regulatory Filings
2025-08-05 English
Clarification on the news item appearing in www.moneycontrol.com
Regulatory Filings
2025-08-01 English
News Verification
Regulatory Filings
2025-08-01 English
Schedule of Earnings call for Unaudited Financial Results of Q1 FY26.
Regulatory Filings
2025-07-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-07-25 English
Lupin Receives U.S. FDA Approvals for Liraglutide and Glucagon Injectable Products.
Regulatory Filings
2025-07-24 English
Press Release
Regulatory Filings
2025-07-24 English
Integrated Report for FY 2024-25 - Revised.
AGM Information
2025-07-23 English
Copy of Newspaper Publication relating to Annual General Meeting and e-voting related information.
Interim / Quarterly Report Q1 2026
2025-07-22 English
Copy of Newspaper Publication
AGM Information
2025-07-22 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-07-21 English
Copy of Newspaper Publication
AGM Information
2025-07-21 English
Copy of Newspaper Intimation relating to Annual General Meeting and e-voting related information.
AGM Information
2025-07-21 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings
2025-07-21 English
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
Regulatory Filings
2025-07-21 English
Updates
Environmental & Social Information
2025-07-19 English
Business Responsibility and Sustainability Report of the Company for FY 2024-25.
Environmental & Social Information
2025-07-19 English
Integrated Report of the Company for FY 2024-25.
AGM Information
2025-07-19 English
Shareholders meeting
AGM Information
2025-07-19 English
Notice of Forty-Third Annual General Meeting of the Company and Integrated Report for FY 2024-25.
AGM Information
2025-07-19 English
Updates
Regulatory Filings
2025-07-17 English
Inspection of U.S. FDA at the Company''s Pithampur Unit-3 manufacturing facility.
Regulatory Filings
2025-07-17 English
Updates
Regulatory Filings
2025-07-17 English
Inspection of U.S. FDA at the Company''s Pithampur Unit-2 manufacturing facility.
Regulatory Filings
2025-07-17 English
Lupin Achieves GMP Certification from TGA Australia for Dabhasa API Facility.
Regulatory Filings
2025-07-17 English
Press Release
Regulatory Filings
2025-07-17 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-07-16 English
Intimation regarding allotment of 31205 equity shares under ESOP.
Share Issue/Capital Change
2025-07-16 English
Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the Unites States
Regulatory Filings
2025-07-16 English
Press Release
Regulatory Filings
2025-07-16 English
Copy of Newspaper Advertisement relating to Annual General Meeting, Record Date and other related information.
Regulatory Filings
2025-07-15 English
Copy of Newspaper Publication
Regulatory Filings
2025-07-15 English
Record Date
Notice of Dividend Amount
2025-07-14 English
Intimation of Record Date for payment of final Dividend, if declared.
Notice of Dividend Amount
2025-07-14 English
Updates
AGM Information
2025-07-14 English
Intimation of the Forty-Third Annual General Meeting of the Company and Record Date for payment of Dividend.
Regulatory Filings
2025-07-14 English
ESG Rating by NSE Sustainability Ratings & Analytics Limited.
Regulatory Filings
2025-07-10 English
General Updates
Regulatory Filings
2025-07-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-07-10 English
Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018, for the quarter ended on June 30, 2025.
Regulatory Filings
2025-07-10 English
Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab.
Regulatory Filings
2025-07-09 English
Press Release
Regulatory Filings
2025-07-09 English
The Company has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin''s biosimilar Certolizumab Pegol.
Capital/Financing Update
2025-07-08 English
Arrangements for strategic, technical, manufacturing, or marketing tie up
Regulatory Filings
2025-07-08 English
Copy of Newspaper publication relating to opening of a special window for re-lodgment of transfer requests for physical shares.
Regulatory Filings
2025-07-07 English
Copy of Newspaper Publication
Regulatory Filings
2025-07-07 English
Press Release
Regulatory Filings
2025-07-04 English
Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States.
Regulatory Filings
2025-07-04 English
Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel.
Regulatory Filings
2025-07-01 English
Press Release
Regulatory Filings
2025-07-01 English
Lupin Carves Out LupinLife Consumer Healthcare.
Capital/Financing Update
2025-07-01 English
Press Release
Capital/Financing Update
2025-07-01 English
Execution of Business Transfer Agreement for transfer of its API R&D Division situated at Pune, to Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of the Company, on a ....
Regulatory Filings
2025-06-30 English
General Updates
Capital/Financing Update
2025-06-30 English
Execution of Business Transfer Agreement for transfer of its Over-the Counter Consumer Healthcare Business to LUPINLIFE Consumer Healthcare Limited, a wholly owned subsidiary of the Company, ....
Capital/Financing Update
2025-06-30 English
General Updates
Capital/Financing Update
2025-06-30 English
Intimation regarding closure of Trading window.
Regulatory Filings
2025-06-27 English
Trading Window
Regulatory Filings
2025-06-27 English
Lupin Launches Prucalopride Tablets in the United States.
Regulatory Filings
2025-06-26 English
Press Release
Regulatory Filings
2025-06-26 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-06-25 English
Press Release
Regulatory Filings
2025-06-25 English
Lupin Receives approval from U.S. FDA for Prucalopride Tablets.
Regulatory Filings
2025-06-25 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-06-24 English
Intimation regarding allotment of 20653 shares under ESOP.
Share Issue/Capital Change
2025-06-24 English
ESOP/ESOS/ESPS
Capital/Financing Update
2025-06-20 English
Intimation regarding grant of 2926 stock options under Lupin Employees Stock Option Plans.
Capital/Financing Update
2025-06-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-06-19 English
Intimation about participating in the Analyst/Institutional Investors Meet.
Regulatory Filings
2025-06-19 English
Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China.
Capital/Financing Update
2025-06-16 English
Press Release
Regulatory Filings
2025-06-16 English
Press Release
Regulatory Filings
2025-06-07 English
Lupin Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets.
Regulatory Filings
2025-06-07 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-05-27 English
Intimation regarding grant of stock options under Lupin Employees Stock Option Plans.
Capital/Financing Update
2025-05-27 English
Intimation of allotment of 78930 shares under ESOP.
Share Issue/Capital Change
2025-05-27 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-05-27 English
Press Release
Investor Presentation
2025-05-26 English
The Company announces presentation of Phase 1 Data on LNP7457, a PRMTS inhibitor at the American Society of Clinical Oncology in Chicago.
Investor Presentation
2025-05-26 English
Press Release
Regulatory Filings
2025-05-26 English
The Company has entered into a license and supply agreement with SteinCares.
Capital/Financing Update
2025-05-26 English
Acquisition
Capital/Financing Update
2025-05-23 English
Disclosure pursuant to Regulation 30 of SEBI Listing Regulations, 2015.
Capital/Financing Update
2025-05-23 English
Transcript of the Investors Meet 2025
Call Transcript
2025-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2025-05-21 English
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers.
Capital/Financing Update
2025-05-20 English
Press Release
Regulatory Filings
2025-05-20 English
Change in Director(s)
Board/Management Information
2025-05-20 English
Re-appointment of Mr. Kanwar Bir Singh Anand as an Independent Director for second term and completion of first term of Dr. Punita Kumar-Sinha as an Independent Director of the Company.
Board/Management Information
2025-05-20 English
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025.
Regulatory Filings
2025-05-19 English
Copy of Newspaper Publication
Regulatory Filings
2025-05-16 English
Copy of Newspaper Publication in respect of Audited Financial Results of the Company for the quarter and year ended March 31, 2025.
Regulatory Filings
2025-05-16 English
The link of audio recording of the Investors Meet 2025 is available on the website of the Company at https://www.lupin.com/audio/q4-fy25-earnings-call.mp3.
Regulatory Filings
2025-05-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-05-15 English
Investor Presentation to be made at the Investors Meet 2025.
Investor Presentation
2025-05-15 English
Investor Presentation
Investor Presentation
2025-05-15 English
Press Release
Board/Management Information
2025-05-15 English
Punita Lal Joins Lupin Board as Additional Director.
Board/Management Information
2025-05-15 English
Press Release
Regulatory Filings
2025-05-15 English
Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg.
Regulatory Filings
2025-05-15 English
Press Release
Annual Report FY 2025
2025-05-14 English
Lupin FY2025 Results
Earnings Release FY 2025
2025-05-14 English
Recommendation of Final Dividend of Rs. 12/- per equity shares i.e. 600% of the face value of Rs. 2/- each fully paid -up for the Financial Year ended March 31, 2025.
Regulatory Filings
2025-05-14 English
Adoption of new sets of Articles of Association of the Company pursuant to the provisions of the Companies Act, 2013.
Board/Management Information
2025-05-14 English
Amendment to AOA/MOA
Board/Management Information
2025-05-14 English
Appointment of M/s. Makarand M. Joshi & Co. Company Secretaries, as Secretarial Auditors of the Company for a term of five consecutive years.
Board/Management Information
2025-05-14 English
General Updates
Board/Management Information
2025-05-14 English
Appointment
Board/Management Information
2025-05-14 English
Appointment of Ms. Punita Lal, as an Additional Director (Non-Executive, Independent) for a term of five years.
Board/Management Information
2025-05-14 English
Dividend
Regulatory Filings
2025-05-14 English
Final Dividend of Rs. 12/- Per Equity Share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year ended March 31, 2025.
Regulatory Filings
2025-05-14 English
Dividend
Regulatory Filings
2025-05-14 English
Outcome of Board Meeting
Regulatory Filings
2025-05-14 English
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2025 and recommend the Final Dividend of Rs. 12/- per Equity Share i.e. 600 % of the Face Value of ....
Regulatory Filings
2025-05-14 English
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2025 and recommend the Final Dividend of Rs. 12/- per Equity Share i.e. 600 % of the Face Value of ....
Regulatory Filings
2025-05-14 English
Press Release
Capital/Financing Update
2025-05-13 English
Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity.
Regulatory Filings
2025-05-13 English
Press Release
Regulatory Filings
2025-05-08 English
Lupin Receives Approval from U.S. FDA for Raltegravir Tablets USP, 600 mg.
Regulatory Filings
2025-05-08 English
Press Release
Regulatory Filings
2025-05-07 English
Lupin Lunches Eslicarbazepine Acetate Tablets in the United States.
Regulatory Filings
2025-05-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-05-02 English
The Company shall be conducting an 'Investors Meet 2025' in Mumbai for Analyst and/or Institutional Investors. The same is scheduled on Thursday, May 15, 2025, at 17.30 hrs (IST).
Regulatory Filings
2025-05-02 English
Updates
Regulatory Filings
2025-04-30 English
Update on transfer of Company''s API R&D Division and Over-the -Counter Consumer Healthcare Business on Slump sale basis.
Regulatory Filings
2025-04-30 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-04-29 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings
2025-04-29 English
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial ....
Regulatory Filings
2025-04-29 English
Intimation regarding allotment of 51495 shares under ESOP.
Share Issue/Capital Change
2025-04-28 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-04-28 English
Lupin Receives Approval from U. S. FDA for Tolvaptan Tablets.
Regulatory Filings
2025-04-24 English
Press Release
Regulatory Filings
2025-04-24 English
Lupin Diagnostics Achieves NABL Accreditation for All Greenfield Labs.
Regulatory Filings
2025-04-23 English
Press Release
Regulatory Filings
2025-04-23 English
Press Release
Regulatory Filings
2025-04-17 English
Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur.
Regulatory Filings
2025-04-17 English
News Verification
Regulatory Filings
2025-04-17 English
The Company has informed the Exchange about court order in the matter of a patent case.
Legal Proceedings Report
2025-04-16 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report
2025-04-16 English
Rumour Verification - Regulation 30(11)
Regulatory Filings
2025-04-16 English
Clarification/ confirmation on the news item appearing in www.cnbctv18.com
Regulatory Filings
2025-04-16 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2025-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-04-07 English
Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018 for the quarter ended on March 31, 2025.
Regulatory Filings
2025-04-07 English
Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company, has acquired the entire share capital of Renascience Pharma Limited, United Kingdom.
M&A Activity
2025-04-02 English
Acquisition
M&A Activity
2025-04-02 English
Modification to the slump sale transaction of transfer of the Over-the-Counter Consumer Healthcare Business.
Regulatory Filings
2025-03-31 English
Other Restructuring
Board/Management Information
2025-03-31 English
Transfer of Company''s API R&D Division to Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company on slump sale basis.
Regulatory Filings
2025-03-31 English
Other Restructuring
Regulatory Filings
2025-03-31 English
Outcome of the Board Meeting held on March 31, 2025.
Board/Management Information
2025-03-31 English
Outcome of Board Meeting
Board/Management Information
2025-03-31 English
Trading Window
Regulatory Filings
2025-03-28 English
Intimation regarding closure of trading window.
Regulatory Filings
2025-03-28 English
Retirement
Board/Management Information
2025-03-28 English
Retirement of Senior Management Personnel(s).
Board/Management Information
2025-03-28 English
Press Release
Regulatory Filings
2025-03-22 English
Lupin Digital Health Introduces Comprehensive Post-Procedure Home-Based Care Guide in Collaboration with the American College of Cardiology.
Regulatory Filings
2025-03-22 English
Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery.
Regulatory Filings
2025-03-21 English
Press Release
Regulatory Filings
2025-03-21 English
Intimation regarding allotment of 24101 shares under ESOP.
Share Issue/Capital Change
2025-03-21 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-03-21 English
Details of voting results of the business transacted by way of Postal Ballot along with report of the Scrutinizer.
Regulatory Filings
2025-03-20 English
Shareholders meeting
Regulatory Filings
2025-03-20 English
Press Release
Environmental & Social Information
2025-03-20 English
Lupin Awarded EcoVadis Silver Medal for Sustainability Excellence, Rank Among the Top 15% Globally.
Environmental & Social Information
2025-03-20 English
General Updates
Regulatory Filings
2025-03-18 English
The Company has incorporated a wholly owned subsidiary in the name and style ''LUPINLIFE Consumer Healthcare Limited'' under Corporate Identification Number U21002MH2025PLC443065.
Regulatory Filings
2025-03-18 English
Lupin Receives Tentative Approval from U.S. FDA for Amifampridine Tablets.
Regulatory Filings
2025-03-17 English
Press Release
Regulatory Filings
2025-03-17 English
Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States.
Regulatory Filings
2025-03-07 English
Press Release
Capital/Financing Update
2025-03-07 English
Intimation regarding allotment of 59940 shares under ESOP.
Share Issue/Capital Change
2025-02-27 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-02-27 English
Press Release
Environmental & Social Information
2025-02-27 English
Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025.
Environmental & Social Information
2025-02-27 English
Lupin Receives EIR from U. S. FDA for its Somerset Manufacturing Facility.
Regulatory Filings
2025-02-21 English
Press Release
Regulatory Filings
2025-02-21 English
Transcript of Q3 FY2025 Earnings Conference Call.
Call Transcript
2025-02-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2025-02-19 English
Intimation about participating in the Analyst/Investors Meet.
Regulatory Filings
2025-02-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-02-19 English
Copy of Newspaper Publication w.r.t. dispatch of Postal Ballot Notice.
Declaration of Voting Results & Voting Rights Announcements
2025-02-19 English
Copy of Newspaper Publication
Proxy Solicitation & Information Statement
2025-02-19 English
Press Release
Environmental & Social Information
2025-02-19 English
Lupin Receives "A-" Leadership Rating from CDP in Two Categories - Climate Change and Water Security.
Environmental & Social Information
2025-02-19 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Postal Ballot Notice.
Proxy Solicitation & Information Statement
2025-02-18 English
Shareholders meeting
Proxy Solicitation & Information Statement
2025-02-18 English
Copy of Newspaper publication in respect of Unaudited Financial Result of the Company for the quarter and nine-months ended December 31, 2024.
Regulatory Filings
2025-02-13 English
Copy of Newspaper Publication
Regulatory Filings
2025-02-13 English
Pursuant to Regulation 30 read with Schedule III Part A Para A(15)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the Earnings Call ....
Regulatory Filings
2025-02-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-02-12 English
Press Release (Revised)
Earnings Release Q3 2025
2025-02-12 English
Lupin Limited has informed regarding a revised Press Release dated February 12, 2025, titled "Lupin Q3 FY2025 Results".
Earnings Release Q3 2025
2025-02-12 English
Investor Presentation - Q3 FY25
Investor Presentation
2025-02-11 English
Investor Presentation
Investor Presentation
2025-02-11 English
Press Release
Interim / Quarterly Report Q3 2025
2025-02-11 English
Lupin Q3 FY2025 Results.
Interim / Quarterly Report Q3 2025
2025-02-11 English
Integrated Filing (Financial) for the quarter ended December 31, 2024.
Interim / Quarterly Report 9M 2025
2025-02-11 English
Integrated Filing- Financial
Interim / Quarterly Report 9M 2025
2025-02-11 English
General Updates
Board/Management Information
2025-02-11 English
Formulation, adoption and implementation of Lupin Employees Stock Option Scheme 2025 for grant of Employee Stock Options to the Eligible Employees of the Company and its subsidiaries under ....
Board/Management Information
2025-02-11 English
Incorporation
Board/Management Information
2025-02-11 English
Incorporation of a wholly-owned subsidiary in the name and style "LUPINLIFE Consumer Healthcare Limited" or any other appropriate name, as may be approved by the Ministry of Corporate Affairs.
Board/Management Information
2025-02-11 English
Other Restructuring
Board/Management Information
2025-02-11 English
Transfer of Over-the-Counter Consumer Healthcare Business of the Company, on slump sale basis, to wholly owned subsidiary that is proposed to be incorporated.
Board/Management Information
2025-02-11 English
Change in Director(s)
Board/Management Information
2025-02-11 English
Re-appointment of Ms. Vinita Gupta as Chief Executive Officer and re-appointment of Mr. Ramesh Swaminathan as Whole-Time Director of the Company.
Board/Management Information
2025-02-11 English
Outcome of Board Meeting
Board/Management Information
2025-02-11 English
Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Board/Management Information
2025-02-11 English
Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31, 2024.
Interim / Quarterly Report 9M 2025
2025-02-11 English
Financial Result Updates
Interim / Quarterly Report 9M 2025
2025-02-11 English
Lupin Receives Approval from U. S. FDA for Ipratropium Bromide Nasal Solution (NASAL Spray), 0.03%
Regulatory Filings
2025-02-10 English
Press Release
Regulatory Filings
2025-02-10 English
Lupin and Natco Receive Approval from U. S. FDA for Bosentan Tablets for Oral Suspension.
Regulatory Filings
2025-02-10 English
Press Release
Regulatory Filings
2025-02-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-02-07 English
Intimation about participating in the Analyst/Institutional Investors Meet.
Regulatory Filings
2025-02-07 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings
2025-02-06 English
Action(s) taken or orders passed
Regulatory Filings
2025-02-06 English
Confirmation on the news item appearing in Mainstream Media titled ''Lupin gets USFDA nod for generic HIC drug''.
Regulatory Filings
2025-02-04 English
Rumour Verification - Regulation 30(11)
Regulatory Filings
2025-02-04 English
Action(s) taken or orders passed
Legal Proceedings Report
2025-02-03 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Legal Proceedings Report
2025-02-03 English
Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations.
Regulatory Filings
2025-02-01 English
Press Release
Regulatory Filings
2025-02-01 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2025-01-30 English
Intimation regarding allotment of 246462 shares under ESOP.
Share Issue/Capital Change
2025-01-30 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-01-27 English
Earnings Call for Q3 FY25 is scheduled on Wednesday, February 12, 2025, at 18:30 hrs (IST).
Regulatory Filings
2025-01-27 English
Board Meeting — Financial Results/Other business matters
Board/Management Information
2025-01-27 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
Board/Management Information
2025-01-27 English
Options to purchase securities
Share Issue/Capital Change
2025-01-20 English
Intimation regarding grant of 233,945 Stock Options
Share Issue/Capital Change
2025-01-20 English
Acquisition
Capital/Financing Update
2025-01-09 English
The Company has completed the acquisition of 42.61% of the equity share capital of Sunsure Solarpark Seventeen Private Limited, in the capacity as a Captive User.
Capital/Financing Update
2025-01-09 English
Lupin Receives EIR from U. S. FDA for its Pithampur Unit-1 Facility with VAI Classification.
Regulatory Filings
2025-01-08 English
Press Release
Regulatory Filings
2025-01-08 English
Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2018.
Regulatory Filings
2025-01-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-01-06 English
Updates
Regulatory Filings
2025-01-02 English
Intimation regarding change in name of Registrar and Share Transfer Agent of the Company.
Regulatory Filings
2025-01-02 English